Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...

Ben Slupecki, CFA, is an equity analyst for Morningstar.* Based in Amsterdam, he covers European business services. Before joining the equity research team, Slupecki was a Morningstar data journalist ...

Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE ...

Johnson & Johnson announced that the US Food and Drug Administration (FDA) has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe ...

Multiple sources within the police hierarchy confirmed to SaharaReporters that the redeployment took effect immediately and has already stirred intense discussion among senior officers and ...

Shares of skin disease concern Oruka Therapeutics, Inc. (ORKA) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study ...

Abstract: In order to weaken the influence of parameter perturbation, nonlinear characteristics and external interference existing in the active suspension system, and improve the performance of ...

Fintel reports that on October 15, 2025, JP Morgan Cazenove reiterated coverage of Pearson plc - Depositary Receipt (NYSE:PSO) with a Overweight recommendation. Analyst Price Forecast Suggests 15.83% ...

Program providers, including those approved as a proprietary system operator (PSO), contracted with Texas Health and Human Services Commission (HHSC) and managed care organizations (MCOs). Financial ...

Shares of Sun Pharma Advanced Research Company (SPARC), the research arm of India’s largest drugmaker Sun Pharma, plunged 19 percent to Rs 158 apiece on June 4 following disappointing Phase 2 trial ...